A. Figure, For better comparability and to overcome the problem of very diverse maximal S/CO values of the antigens, the S/CO values are depicted as " non-reactive " in black (S/CO value < 1) or in colors as indicated for five different levels (five indicates highest reactivity) The S/CO levels for all antigens are shown in Table A1. Each illustrated sample is the first sample of a time course. Time courses were obtained from 15 patients without and 11 patients with spontaneous viral clearance

J. P. Messina, I. Humphreys, A. Flaxman, A. Brown, G. S. Cooke et al., Global distribution and prevalence of hepatitis C virus genotypes, Hepatology, vol.7, issue.2, pp.77-87, 2015.
DOI : 10.1371/journal.pone.0028006

L. B. Seeff, Natural history of chronic hepatitis C, Hepatology, vol.36, pp.35-46, 2002.
DOI : 10.1053/jhep.2002.36806

D. L. Thomas and L. Seeff, Natural history of hepatitis C. Clin. Liver Dis, pp.383-398, 2005.

J. M. Pawlotsky, Use and interpretation of virological tests for hepatitis C, Hepatology, vol.36, pp.65-73, 2002.

P. Farci, H. J. Alter, D. Wong, R. H. Miller, J. W. Shih et al., A Long-Term Study of Hepatitis C Virus Replication in Non-A, Non-B Hepatitis, New England Journal of Medicine, vol.325, issue.2, pp.98-104, 1991.
DOI : 10.1056/NEJM199107113250205

P. Marcellin, Hepatitis C: the clinical spectrum of the disease, Journal of Hepatology, vol.31, pp.31-40, 1999.
DOI : 10.1016/S0168-8278(99)80368-7

W. Vogel, I. Graziadei, F. Umlauft, C. Datz, F. Hackl et al., High-dose interferon-??2b treatment prevents chronicity in acute hepatitis C, Digestive Diseases and Sciences, vol.99, issue.suppl 2, pp.81-85, 1996.
DOI : 10.1016/0016-5085(90)90626-C

E. Jaeckel, M. Cornberg, H. Wedemeyer, T. Santantonio, J. Mayer et al., Treatment of Acute Hepatitis C with Interferon Alfa-2b, New England Journal of Medicine, vol.345, issue.20, pp.1452-1457, 2001.
DOI : 10.1056/NEJMoa011232

A. Licata, D. Di-bona, F. Schepis, L. Shahied, A. Craxi et al., When and how to treat acute hepatitis C?, Journal of Hepatology, vol.39, issue.6, pp.1056-1062, 2003.
DOI : 10.1016/S0168-8278(03)00461-6

J. T. Gerlach, H. M. Diepolder, R. Zachoval, N. H. Gruener, M. C. Jung et al., Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance1 1The Bundesministerium f??r Bildung und Forschung and the European Union, as sponsors of the study, had no role in study design, data collection, analysis, or interpretation or in the writing and the decision to submit the report for publication., Gastroenterology, vol.125, issue.1, pp.80-88, 2003.
DOI : 10.1016/S0016-5085(03)00668-1

E. Naggar, K. M. Rasenack, and J. , Peginterferon ?2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response, Gastroenterology, vol.130, pp.632-638, 2006.

K. Deterding, N. Grüner, P. Buggisch, J. Wiegand, P. R. Galle et al., Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial, The Lancet Infectious Diseases, vol.13, issue.6, pp.497-506, 2013.
DOI : 10.1016/S1473-3099(13)70059-8

H. Planatscher, S. Rimmele, G. Michel, O. Potz, T. Joos et al., Systematic reference sample generation for multiplexed serological assays, Scientific Reports, vol.2, issue.1
DOI : 10.1371/journal.pntd.0000316
URL : http://www.nature.com/articles/srep03259.pdf

D. Bonnefont-rousselot and B. Souberbielle, Schuppe-Koistinen, I.; et al. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI), Regul. Toxicol. Pharmacol, vol.60, pp.290-295, 2011.

A. C. Araujo, I. V. Astrakhantseva, H. A. Fields, and S. Kamili, Distinguishing Acute from Chronic Hepatitis C Virus (HCV) Infection Based on Antibody Reactivities to Specific HCV Structural and Nonstructural Proteins, Journal of Clinical Microbiology, vol.49, issue.1, pp.54-57, 2011.
DOI : 10.1128/JCM.01064-10
URL : http://jcm.asm.org/content/49/1/54.full.pdf

R. Castillo, Incidence of non-A, non-B hepatitis after screening blood donors for antibodies to hepatitis C virus and surrogate markers, Ann. Intern. Med, vol.115, pp.596-600, 1991.

D. Xu, H. Lu, J. Nu, Z. Meng, D. Shang et al., Dynamic study of anti-NS5 and ALT in post-transfusion hepatitis C, Chinese), pp.344-347, 1997.

J. Y. Lau and Q. L. Choo, A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells, Proc. Natl. Acad. Sci, pp.1759-1763, 1996.

P. Meuleman, J. Bukh, L. Verhoye, A. Farhoudi, T. Vanwolleghem et al., evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus, Hepatology, vol.83, issue.Pt 6, pp.755-762, 2011.
DOI : 10.1128/JVI.01138-09

Y. Wang, Z. Y. Keck, and S. K. Foung, Neutralizing Antibody Response to Hepatitis C Virus, Viruses, vol.3, issue.12, pp.2127-2145, 2011.
DOI : 10.3390/v3112127
URL : https://doi.org/10.3390/v3112127

S. Abrignani and P. Balfe, Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies, Vaccine, vol.25, pp.7773-7784, 2007.

C. Castelnau, M. Pouteau, and T. Asselah, Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody, Liver Int, vol.29, pp.511-517, 2009.

K. Hayashi and I. Nakano, Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy, Clin. Infect. Dis, vol.40, pp.49-54, 2005.